United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Net Income (Common)
United Therapeutics Corp
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Net Income (Common)
$984.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
19%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is United Therapeutics Corp's Net Income (Common)?
Net Income (Common)
984.8m
USD
Based on the financial report for Dec 31, 2023, United Therapeutics Corp's Net Income (Common) amounts to 984.8m USD.
What is United Therapeutics Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
19%
Over the last year, the Net Income (Common) growth was 35%. The average annual Net Income (Common) growth rates for United Therapeutics Corp have been 24% over the past three years , 11% over the past five years , and 19% over the past ten years .